Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sorafenib in Triple Negative Breast Cancer
NCT01194869Phase 2Terminated
- Sponsor
- Emory University
- Start
- Jun 2010
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in triple negative breast cancer (TNBC), sponsored by Emory University. Started Jun 2010; status: terminated.
02
Drugs
sorafenib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01194869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194869.